ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
99.80
+1.16 (1.18%)
Nov 5, 2025, 1:58 PM EST - Market open
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.05M EUR in the quarter ending June 30, 2025, a decrease of -81.34%. This brings the company's revenue in the last twelve months to 6.02M, down -33.90% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
6.02M EUR
Revenue Growth
-33.90%
P/S Ratio
1,084.26
Revenue / Employee
87,290 EUR
Employees
69
Market Cap
7.67B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ABVX News
- 22 days ago - Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster - Seeking Alpha
- 4 weeks ago - ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 4 weeks ago - Why Is Abivax Stock Trading Higher On Monday? - Benzinga
- 4 weeks ago - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewsWire
- 5 weeks ago - Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 6 weeks ago - Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 7 weeks ago - Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - GlobeNewsWire
- 2 months ago - Abivax Presents First Half 2025 Financial Results - GlobeNewsWire